Jasper Therapeutics, Inc.

NasdaqCM:JSPR Stock Report

Market Cap: US$31.9m

Jasper Therapeutics Management

Management criteria checks 1/4

Jasper Therapeutics' CEO is Jeet Mahal, appointed in Mar 2022, has a tenure of 3.92 years. total yearly compensation is $1.28M, comprised of 37.7% salary and 62.3% bonuses, including company stock and options. directly owns 0.089% of the company’s shares, worth $28.51K. The average tenure of the management team and the board of directors is 2.4 years and 2.9 years respectively.

Key information

Jeet Mahal

Chief executive officer

US$1.3m

Total compensation

CEO salary percentage37.66%
CEO tenure3.9yrs
CEO ownership0.09%
Management average tenure2.4yrs
Board average tenure2.9yrs

Recent management updates

Recent updates

Companies Like Jasper Therapeutics (NASDAQ:JSPR) Could Be Quite Risky

Jan 08
Companies Like Jasper Therapeutics (NASDAQ:JSPR) Could Be Quite Risky

Here's Why Jasper Therapeutics (NASDAQ:JSPR) Must Use Its Cash Wisely

May 30
Here's Why Jasper Therapeutics (NASDAQ:JSPR) Must Use Its Cash Wisely

Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Deliver On Growth Plans?

Jan 04
Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Deliver On Growth Plans?

Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma

Nov 18

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Aug 30
We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully

Jan 23
We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully

Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth

Jul 31
Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Feb 02
We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash Wisely

Oct 14
Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash Wisely

Jasper Therapeutics GAAP EPS of -$0.29 beats by $0.02

Aug 12

Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Invest In Growth?

Jun 19
Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Invest In Growth?

CEO Compensation Analysis

How has Jeet Mahal's remuneration changed compared to Jasper Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$91m

Jun 30 2025n/an/a

-US$91m

Mar 31 2025n/an/a

-US$79m

Dec 31 2024US$1mUS$481k

-US$71m

Sep 30 2024n/an/a

-US$64m

Jun 30 2024n/an/a

-US$62m

Mar 31 2024n/an/a

-US$64m

Dec 31 2023US$1mUS$462k

-US$64m

Sep 30 2023n/an/a

-US$61m

Jun 30 2023n/an/a

-US$55m

Mar 31 2023n/an/a

-US$50m

Dec 31 2022US$1mUS$418k

-US$38m

Sep 30 2022n/an/a

-US$34m

Jun 30 2022n/an/a

-US$25m

Mar 31 2022n/an/a

-US$23m

Dec 31 2021US$461kUS$355k

-US$31m

Sep 30 2021n/an/a

-US$32m

Jun 30 2021n/an/a

-US$39m

Mar 31 2021n/an/a

-US$40m

Dec 31 2020US$720kUS$330k

-US$32m

Compensation vs Market: Jeet's total compensation ($USD1.28M) is above average for companies of similar size in the US market ($USD577.34K).

Compensation vs Earnings: Jeet's compensation has increased whilst the company is unprofitable.

CEO

Jeet Mahal (52 yo)

3.9yrs
Tenure
US$1,278,131
Compensation

Mr. Jeetinder Singh Mahal, also Known as Jeet, M.B.A., M.E., M.B., serves as President, CEO & Director from January 5, 2026 and served as Chief Financial of Jasper Therapeutics, Inc. since December 2019 un...

Leadership Team

NamePositionTenureCompensationOwnership
Thomas Wiggans
Executive Chairman2.3yrsUS$231.49k0.16%
$ 52.4k
Jeetinder Mahal
President3.9yrsUS$1.28m0.089%
$ 28.5k
Judith Shizuru
Co-Founderno dataUS$457.79k0.56%
$ 178.9k
Herbert Cross
CFO & Corporate Secretary2.4yrsUS$1.27m0%
$ 0
Alex Gray
Head of Investor Relationsno datano datano data
Matthew Ford
Senior Vice President of Human Resources3.1yrsno datano data
Daniel Adelman
Acting Chief Medical Officerless than a yearno datano data
Luca Di Noto
Senior Vice President of Technical Operationsno datano datano data
Patricia Carlos
Senior Vice President of Regulatory Affairs & Quality2.5yrsno datano data
Kimberly Baxter
VP & Head of Quality2.1yrsno datano data
2.4yrs
Average Tenure
68yo
Average Age

Experienced Management: JSPR's management team is considered experienced (2.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Thomas Wiggans
Executive Chairman2.3yrsUS$231.49k0.16%
$ 52.4k
Jeetinder Mahal
Presidentless than a yearUS$1.28m0.089%
$ 28.5k
Judith Shizuru
Co-Founder7.9yrsUS$457.79k0.56%
$ 178.9k
Daniel Adelman
Acting Chief Medical Officer2.7yrsno datano data
Kurt von Emster
Independent Director6.3yrsUS$228.29k0.0076%
$ 2.4k
Arthur Weiss
Member of Scientific Advisory Boardno datano datano data
Frederick Appelbaum
Member of Scientific Advisory Boardno datano datano data
Jeffrey Ravetch
Member of Scientific Advisory Boardno datano datano data
Stephen Galli
Member of Scientific Advisory Board2.8yrsno datano data
Vishal Kapoor
Independent Director3yrsUS$212.99k0.016%
$ 5.0k
Harry Malech
Member of Scientific Advisory Boardno datano datano data
Christian Nolet
Independent Director4.4yrsUS$226.49k0.012%
$ 3.7k
2.9yrs
Average Tenure
68yo
Average Age

Experienced Board: JSPR's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/16 09:30
End of Day Share Price 2026/02/13 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Jasper Therapeutics, Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Justin ZelinBTIG
Timothy ChiangCapital One Securities, Inc.
Silvan TuerkcanCitizens JMP Securities, LLC